ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / LIVN
ITGR (67) AXGN (54) TMDX (62) CNMD (65) ⌘ Pro Terminal →

LivaNova PLC (LIVN) — RQD Stock Rating Cockpit

$78.97 -2.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $78.42

LivaNova PLC (LIVN) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY) →
ROARABLE C+ • HOLD / WATCH Cap $4.48B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LIVN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, LivaNova PLC (NASDAQ: LIVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $78.97 (-2.81% 1D, market cap $4.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LIVN ranks #102 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LIVN compare to ITGR and AXGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C+ (68/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LIVN?
▼

Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $78.42 (-0.70%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 12.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510068
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C
Cash (16)Whales (15)SEC (12)Macro (13)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+4.5% Base Target
$97 Bull$83 Base$64 Bear
📬 FREE LIVN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIVN)Realized 20D OHLCV Swing Band: ±5.8%
Deterministic 5-Pillar Attribution (68/100 Composite)
🔍 WHY LIVN SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($173.3M FCF) & 67.7% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)

20D Institutional Volume Accumulation (±5.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
60
Grade C$77.27+1.1% Next Q
Q2 (-2Q)
63
Grade C+$78.14+3.2% Next Q
Q3 (-1Q)
65
Grade C+$80.62-2% Next Q
Current
68
Grade C+$78.97+1.8% Hist 90D α
Trajectory: C (60) → C+ (68)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LIVN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, LIVN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($78.54) or 200D SMA ($72.99) invalidates the momentum regime and cuts Target Base ($82.52) toward Bear Floor ($64.37).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LIVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 68%NO 32%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
58.230 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.21>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE82% OF RANGE
L: $49$78.97H: $86
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (68% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on LIVN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

17.3% ROIC with 67.7% gross margin and 3.87% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 2.21 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (67)

27/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like LIVN
  • ✓Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LIVN Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LIVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.69%📐 HORIZONTAL RANGE
2026-11-02O $80.66H $81.25L $78.97C $78.97VOL 483.3K
RES: $81.85SUP: $74.06SMA50: $78.54SMA200: $72.99
$87.81$79.31$70.81$62.30$53.80RES $81.85SUP $74.06$78.972026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIVN Butterfly Map → + Track LIVN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
13.0%/yr Implied 5Y Growth

vs. +10.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LIVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LIVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIVN)

Health Care Rank #102 of 1016 ⚔️ ITGR vs LIVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIVN vs. ITGR, AXGN, TMDX, CNMD)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LivaNova PLC (LIVN) ranks #102 by composite RQD confidence (68/100, grade C+) and #171 by equity capitalization ($4.48B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. LIVN currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LIVN ACTIVE
LivaNova PLC
C+ 68/100 — 67.7% 17.3% -2.81% $4.48B Benchmark Subject
ITGR
Integer Holdings Corporation
C+ 67/100 41.8x 27.0% 6.0% +0.06% $4.30B /itgr-vs-livn →
AXGN
Axogen Inc.
D+ 54/100 — 74.3% -2.6% -0.52% $2.96B /axgn-vs-livn →
TMDX
TransMedics Group Inc.
C 62/100 12.2x 59.9% 18.1% -1.68% $2.33B /tmdx-vs-livn →
CNMD
CONMED Corporation
C 65/100 28.9x 54.6% 7.8% -3.13% $1.36B /cnmd-vs-livn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001639691

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LivaNova PLC (LIVN) reported GAAP revenue of $1.39B (+10.7% vs. FY2024 revenue of $1.25B , and +20.3% cumulative change since FY2023) , GAAP net income of -$242.5M, operating cash flow of $254.3M, and free cash flow of $173.3M (+27.5% YoY). On the balance sheet, LIVN closed FY2025 with $2.61B in total assets against $345.2M in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.39B -$242.5M $254.3M $173.3M $2.61B $345.2M
FY2024 (FY) 2024-12-31 $1.25B $63.2M $183.0M $135.9M $2.51B $549.6M
FY2023 (FY) 2023-12-31 $1.15B $17.6M $74.9M $74.9M — —

3. LIVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, LivaNova PLC (NASDAQ: LIVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $78.97 (-2.81% 1D, market cap $4.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LIVN ranks #102 in composite RQD confidence.

How does LIVN compare to ITGR and AXGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C+ (68/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LIVN?

Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LIVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIVN last traded at $78.97 (-2.81% on volume of 575,628 shares), positioning the stock +0.55% above its 50-day simple moving average ($78.54) and +8.19% above its 200-day simple moving average ($72.99). Across its 52-week range of $48.82 to $85.76, LIVN sits at the 81.6% percentile with a 14-day RSI of 58.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.8% ($74.39 to $83.55).

LIVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LIVN stock right now?

LivaNova PLC (LIVN) currently earns a Roarable Rating of C+ (Hold — HOLD) with 68/100 RQD Confidence. Solid 68% profit margin (17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

What is LIVN's 12-month price target and RQD AI Jury consensus?

LIVN's 12-month base price target is $82.52 (range $64.37 to $97.37), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LIVN RQD Cockpit LIVN 12M Forecast LIVN Earnings & Move LIVN Dividends & DRIP LIVN Insiders & 13F LIVN Whale Options LIVN Profit Sankey LIVN News & Why
ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LIVN — LivaNova PLC: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:21:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LIVN scores 68 out of 100, earning a C+ grade and the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:

  • Fundamental Cash Engine: 16 / 20. Per the Roarable RQD rating, this pillar cites ROIC of 17.3% and an FCF yield of 3.87%. For a prospective investor, the return on invested capital is a constructive signal, while the FCF yield implies the market is paying a moderate price for each dollar of free cash flow generated.
  • Whale / 13F Flow: 15 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying 13F and options detail is not itemized in the source data, so the score is a summary rather than a traceable position count.
  • Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data.
  • Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 1.0 and the score reflects sector sensitivity. For a prospective investor, a beta of 1.0 implies the stock has historically moved in line with the broader market; it does not indicate defensive or aggressive behavior relative to the market.
  • Forensic Balance Sheet: 12 / 20. Per the Roarable RQD rating, this pillar cites an Altman Z-Score of 2.21, a Piotroski F-Score of 7/9, and Debt/Equity of 0.29. These figures suggest a moderate balance sheet posture with no acute distress signal in the source data.

Taken together, the rating points to a stock with solid cash returns and a workable balance sheet, offset by mid-range ownership and insider signals and a beta-neutral macro profile. The "Watch for Breakout" language indicates the rating sits near the upper end of neutral, so the upside case depends on the cash engine and sentiment signals improving, while valuation (EV/EBITDA of 15.6) limits how much multiple expansion the current setup supports.

Business

LivaNova PLC is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry, per the company profile. The profile describes it as a market capitalization of $4.5B issuer. Products, customer segments, and revenue mechanics are not itemized in the source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$1388.1M$199.4M$-242.5MN/A$173.3M$635.6M$345.2M
FY 2024$1253.4M$129.1M$63.2MN/A$135.9M$428.9M$549.6M
FY 2023$1153.5M$-68.5M$17.6MN/A$74.9MN/AN/A

Per the SEC financials, revenue rose from $1153.5M in FY 2023 to $1388.1M in FY 2025, and operating income moved from $-68.5M to $199.4M over the same span. FY 2025 reported a net loss of $-242.5M despite positive operating income, and the market data shows a net margin of -17.5% against a gross margin of 67.7% and operating margin of 14.4%. Per the Roarable RQD rating, ROIC is 17.3%, the Altman Z-Score is 2.21, and the Piotroski F-Score is 7/9. Debt per the SEC financials declined from $549.6M in FY 2024 to $345.2M in FY 2025, while cash rose to $635.6M; Debt/Equity is 0.29 per the Roarable RQD rating.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, five headlines reference LIVN:

  • A Yahoo Finance report on market action and institutional positioning (marked YELLOW, Market Wire).
  • A ChartMill report describing the stock as an affordable growth candidate with reasonable valuation (marked GREEN, Catalyst).
  • A Yahoo Finance stock forecasts item (marked YELLOW, Market Wire).
  • A GuruFocus report on a 36-month CORE-VNS study publication (marked YELLOW, Market Wire).
  • Two Simply Wall St pieces, one on CORE VNS results as a potential turning point and one on long-term epilepsy data, both marked YELLOW.

The CORE-VNS and epilepsy-data items are the recurring clinical theme in the news flow; the specific study outcomes are not detailed in the source data. The Butterfly supply-chain graph contains no signals (see below). Risk watch items are not separately itemized beyond the YELLOW classifications.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and cross-sector correlations are therefore not available in source data. A prospective investor should note that 2nd-order ripple effects cannot be mapped from the provided material; the clinical-data theme in the news flow is the only sector-level thread visible.

Open Questions

  • What are the specific clinical outcomes of the 36-month CORE-VNS study, and how do they bear on revenue?
  • What drove the FY 2025 net loss of $-242.5M despite positive operating income of $199.4M?
  • What are the P/E and EPS figures on a trailing and forward basis, which the source data leaves unavailable?
  • Who are the institutional and insider holders behind the RQD flow pillars, and what are their position sizes?
  • What is the consensus analyst rating and price target, given that no analyst data was supplied?

LIVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LivaNova PLC (LIVN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LIVN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LIVN Bull vs. Bear Conversation Board — What's Your Call at $78.97?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LIVN 🐻 50% BEARISH CONVICTION
1. Pick Your Side on LIVN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $87.75 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LIVN (C+ • RQD 68/100) a Buy at $81.25?

Welcome to the LIVN (LivaNova PLC) Roar Pit. Current RQD Composite is 68/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to capital efficiency (17.3% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $60.94 (-25.0%)
Spot @ $81.25

Pump the brakes on LIVN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LIVN, but look at what you are paying: current EV/EBITDA multiples with 67.7% gross margins. Unless LivaNova PLC expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $99.94 (+23.0%)
Spot @ $81.25

LIVN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LIVN, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $81.25 (52-wk range $48.82 - $85.76), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%